Up 247% - Eton Pharmaceuticals Q2 Earnings

To read our full disclaimer, click here:

No paywall on this one.

The whole post is free, to everyone, the same way I made the entire body of work on this name free back in May.

Eton Pharmaceuticals (NASDAQ: ETON) reported Q2 2026 after the close on Thursday.

The stock finished Friday up 44%.

Three numbers to set the scene:

1. Up 247% since I first wrote the company up in November 2025 at $16.92.

2. Up around 95% since the last major update, which I made free to every subscriber in May.

3. Up 60% since the Model Portfolio went live on the 1st of July, 45 days ago. It went in as one of the larger positions. After Friday it’s the largest holding in the portfolio at roughly 12%.

Past performance is not a reliable indicator of future results. Nothing here is a personal recommendation, and share prices can fall as well as rise.

The rest of this post is the actual Q2 breakdown: what was in the quarter, what management said on the call, and my honest thoughts on where it goes from here.

Let’s dig in…

• Revenue of $37.6 million, up 99% year-on-year from $18.9 million. A record quarter.

• Gross profit of $25.4 million, up 113%. Adjusted gross margin of 73%, down from 75%.

• R&D of $1.0 million, down from $3.7 million.

• G&A of $11.6 million, up 20% from $9.7 million.

• EBITDA of $14.1 million, against a $0.3 million loss a year ago.

• Adjusted EBITDA of $16.2 million, or 43% of revenue, up from $3.1 million and 16%.

• GAAP net income of $11.6 million, or $0.35 per diluted share, against a $2.6 million loss.

• Non-GAAP net income of $14.3 million, or $0.43 per diluted share.

• Cash of $26.8 million at June 30, after a $3 million voluntary debt prepayment.

Net income margin of roughly 31% on a GAAP basis.

For a company that was posting losses this time last year, that’s the line that stands out most to me.

Eton now has eleven commercial rare disease products and five late-stage development candidates.

When I first wrote it up it was eight and five.

HEMANGEOL was the largest single contributor to growth in the quarter, and it’s now Eton’s largest product.

Quick recap for anyone new or needs a reminder:

HEMANGEOL is the only FDA-approved treatment for infantile haemangiomas - benign vascular tumours in babies. Eton bought it in early 2026 for $14 million in cash and relaunched it on May 1st, moving the entire patient base off eighteen separate pharmacies onto a single channel through Anovo, with full Eton Cares support and a $0 copay for eligible commercially insured patients.

Management budgeted three to four months for that transition.

Infantile haemangioma therapy only lasts about six months, so they weren’t moving a static population - they were converting existing patients, onboarding newly diagnosed infants, and supporting patients finishing therapy, all at the same time.

They were at 95% converted by the end of June. On the call, Chief Business Officer David Krempa went further: “We think we have got them all now.”

The economics management has guided to: historically around 8,000 patients a year are treated with HEMANGEOL, at a net realised price of $8,000 to $10,000 per treated patient for a full course. Krempa confirmed on Thursday that the transition hasn’t changed that: “It’s more or less in the ballpark.”

Eton doesn’t break out product-level revenue and said again on the call that they won’t, so nobody outside the company knows the exact number. But that’s the framework management has given, and it explains a lot of the guidance raise.

The other change is on cost.

Families were previously paying roughly $55 per bottle, which could run past $100 a month. That’s now $0 for eligible patients.

Management’s argument is that the out-of-pocket cost was pushing doctors toward off-label alternatives, and removing it opens up volume that was never being captured.

Ninety days after entering paediatric dermatology, Eton licensed ASN-001, a late-stage candidate developed specifically for moderate infantile haemangiomas.

The logic here is worth understanding properly, because management thinks this becomes the largest product in the company.

HEMANGEOL treats severe cases - Eton sizes that at 10,000 to 15,000 patients a year.

But infantile haemangiomas affect more than 100,000 infants annually in the US across a spectrum of severity. Eton estimates around 10,000 infants a year with moderate haemangiomas are being treated off-label with ophthalmic timolol - a glaucoma eye drop, never developed for infants, with variable dosing, no approved labelling and no reimbursement pathway.

ASN-001 is designed for exactly that gap.

It’s already completed a Phase III trial showing efficacy against placebo. The only remaining development requirement is a bioavailability bridging study - a 24-patient, 29-day PK study with a protocol the FDA has already reviewed, costing roughly $4 million over the next twelve months.

CEO Sean Brynjelsen on the risk profile:

“We view it as very straightforward and low risk.”

NDA submission is planned for the second half of 2027, with launch expected in 2028. Combined with HEMANGEOL, management sizes the addressable market at 20,000 to 30,000 patients annually.

Three reasons they think it becomes the biggest product:

• The patient population is two to three times larger

• It’s prescribed by the same doctors so it leverages the sales force Eton already built

• As a new launch it avoids the rebate dynamics that weigh on HEMANGEOL’s gross-to-net.

Better net pricing on a bigger population.

Cost to secure it: a $3 million upfront licensing payment, expensed as R&D in Q3.

There’s a second reason ASN-001 matters, and it only came up 45 minutes into the call, when an analyst asked about it.

The HEMANGEOL patent expires in October 2028. Brynjelsen’s answer was that there are formulation improvements they’re working on that could add IP, and that ASN-001 has “a very, obviously, long runway in terms of patent protection.”

So the franchise strategy is: HEMANGEOL provides the cash flow and the commercial foothold now, ASN-001 arrives in 2028 as the durable asset.

This was the original core of the business and it’s still growing.

• ALKINDI SPRINKLE and KHINDIVI - the adrenal franchise - crossed 600 active patients, against a stated goal of 1,000. The new KHINDIVI formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and Eton has filed a Prior Approval Supplement with the FDA to expand the label to patients under five years old. Approval is targeted for the first half of 2027. Management believes the largest unmet need for an FDA-approved oral liquid hydrocortisone sits in that under-five group.

• DESMODA, the oral liquid desmopressin approved in February, launched in March and is running at about 115% of internal patient-add targets. Peak sales guidance is unchanged at $40 to $50 million. Brynjelsen was honest about the near-term contribution: “It wasn’t a huge contributor to the growth that you saw in Q2.” This is a 2027 story rather than a 2026 one, and it’s also opening the door to adult endocrinologists, which extends Eton’s commercial reach beyond its traditional paediatric call point.

• INCRELEX delivered strong year-on-year growth. The label harmonisation study now has FDA sign-off on the protocol and a CRO contracted, with first patient dosing targeted by year-end. If the US definition of severe primary IGF-1 deficiency is broadened to match the EU definition, the addressable population goes from roughly 200 patients to 1,000.

• AMGLIDIA, a liquid glyburide for neonatal diabetes, received FDA Fast Track designation. The bioavailability study starts this month, NDA submission is planned by year-end, and management intends to request priority review. Approval and launch targeted for 2027. It’s a tiny population - a few hundred children in the US - but there’s currently no approved oral treatment for the condition at all.

GALZIN delivered another strong quarter of patient additions. Management says they’ve still converted less than half of patients currently managed on over-the-counter zinc products, so the conversion runway is far from finished.

The more interesting item is ET-700, Eton’s proprietary patent-pending extended-release zinc acetate formulation.

The pilot study is underway: a double-blind, placebo-controlled trial in 36 healthy volunteers, using PET scans with radioactive tracer copper to compare intestinal copper absorption across ET-700, GALZIN and placebo.

Initial results are expected within the next month or two, with the full report by year-end. If the pilot works, a pivotal study starts in early 2027. Management believes ET-700 could exceed $100 million in peak annual US sales.

That’s the nearest binary event in the whole story, and it’s weeks away.

Eton acquired exclusive US commercialisation rights to IMPAVIDO in June, under a supply and distribution agreement with Knight effective May 18, 2026. Launch is planned for late September.

IMPAVIDO is the only FDA-approved oral therapy for leishmaniasis, a rare parasitic disease that can cause severe skin lesions, disfiguring mucosal disease or life-threatening visceral infection.

The commercial thesis is straightforward.

Chief Commercial Officer Ipek Trinkaus explained that it was previously distributed through “basically a single-person distributor structure” - no field sales force, no copay support, no Medicaid coverage, and dispersed distribution that made it hard for patients to work out where to get the product.

Eton counts roughly 300 sales targets, a concentrated call point its existing specialty infrastructure can cover, and it’s going into the Eton Cares model with $0 copay support.

Knight retains all rights, title and interest in the product and handles manufacturing and supply; Eton holds the US marketing authorisation as nominee and carries all commercialisation, sales and compliance costs.

There are minimum annual net sales thresholds and minimum order quantities.

Krempa was upfront that a large profit share goes to Knight and that it will be “lower margin than some of our other products”, contributing “multiple millions annually.”

Very little capital at risk, a good return on that capital, but not a needle-mover.

• Full-year 2026 revenue guidance went from more than $120 million to more than $145 million.

• Adjusted EBITDA margin guidance went from at least 30% to at least 35%.

• Full-year adjusted gross margin is expected to exceed 70%.

The margin raise is the one I’d pay attention to, because of what management chose to absorb inside it:

• The $3 million ASN-001 upfront licensing payment, expensed in Q3

• Incremental second-half R&D for the ASN-001 bioavailability study

• A potential one-time $4 million ALKINDI SPRINKLE commercial milestone payment in Q4, which only triggers if sales hit certain thresholds

• Startup costs for the INCRELEX label harmonisation study

• The AMGLIDIA bioavailability study

• IMPAVIDO launch costs from late September

Full-year R&D is guided to $10 to $14 million against just $2.9 million spent in the first half. So second-half R&D runs three to four times the first-half rate, and the 35% margin guide is after all of it.

On the longer-term targets, management updated all three:

• Exit 2027 at a $200 million annualised revenue run rate. Brynjelsen: “We now believe that Eton is well ahead of this goal.”

• 50% adjusted EBITDA margin in 2028. They hit 43% in Q2, in a quarter that included a brand new launch.

• $500 million of annual revenue by 2030. With ASN-001 added, “Eton expects to achieve or exceed this goal.”

This is the part of the Eton story I’ve always liked most, and this quarter is the cleanest expression of it.

In the first half, Eton spent $15 million on product licensing rights, prepaid $3 million of debt voluntarily, and funded a $13.1 million build in accounts receivable as revenue nearly doubled. It generated $14.7 million of operating cash flow to do it.

Cash finished at $26.8 million, against $25.9 million at the start of the year. Two acquisitions, a full product relaunch, and cash went up.

No equity issued. No new debt drawn. Share count moved from 27.0 million to 28.3 million, and that’s option exercises and the employee share purchase plan, not a raise.

Total debt sits at roughly $27.9 million against $26.8 million of cash - effectively net debt free.

CFO Judy Matthews said the plan is to keep funding accretive product acquisitions from cash reserves while accelerating repayment of the remaining credit facility over the next six to twelve months.

Back in May I said the risk I was watching closest was whether balance sheet pressure would force a dilutive financing.

Four months and two deals later, that risk is materially lower than it was in my opinion.

• The HEMANGEOL patent expires in October 2028. That’s the single most important date in this thesis and it got about ninety seconds of airtime on a fifty-minute call. Management’s answer is formulation improvements plus ASN-001. I think that’s a reasonable answer. But ASN-001 doesn’t launch until 2028, which means the handover has to be close to perfect. Any slip in the bioavailability study or the NDA timeline and there’s a gap.

• Q3 is the first clean read on HEMANGEOL. Q2 included a chaotic transition quarter with bridge product and channel noise. Q3 is the first full quarter under the new model with the conversion complete. If HEMANGEOL doesn’t grow sequentially from here, the run rate everyone is now assuming is wrong.

• The ET-700 pilot could fail. Initial results land within weeks. A negative read takes out a programme management sizes at $100 million-plus in peak sales, and it’s the first real test of whether Eton’s development judgement matches its acquisition judgement.

• Receivables. Accounts receivable more than doubled to $24.9 million and now sit at about 66% of quarterly revenue. Some of that is simply fast growth plus a new specialty pharmacy channel that hasn’t settled into a payment rhythm. But if revenue grows next quarter and receivables grow faster again, the quality of these earnings gests a question mark it doesn’t currently deserve.

• The valuation allowance. Eton carries a roughly $22 million valuation allowance against deferred tax assets. Matthews flagged that if the company exits its cumulative loss position in the second half of 2026, some or all of it may be released, producing “a significant one-time non-cash income tax benefit and a corresponding increase in reported GAAP net income.” Know that in advance. If Eton prints a huge GAAP EPS number in Q4 or Q1, a chunk of it may be an accounting entry rather than earnings. Adjusted EBITDA is the number to hold on to.

• The gross margin drag. Adjusted gross margin fell from 75% to 73%, caused by $2.9 million of INCRELEX and GALZIN sales made outside the US, which carry a negative gross margin. That’s a legacy of the ex-US arrangement rather than a pricing problem in the core business, but it scales with international volume.

• Acquisition discipline. Every deal so far has been small, cash-funded, and accretive quickly. Brynjelsen noted that growing profitability “has expanded our financial capacity, allowing us to pursue a broader range of transactions, including potentially larger opportunities.” Larger opportunities are where rollups historically go wrong.

I’m not going to sit here and tell you a 44% day was obviously correct.

A move that size in a company this size is partly information and partly a very small float meeting a lot of new attention at once.

Both things are true.

What I can tell you is what changed in the business, because that’s the part that lasts.

I don’t think the market is repricing one good quarter.

I think it’s repricing the realisation that this is a repeatable process rather than a series of lucky trades.

Small bets, high returns on capital, no competition for the assets, funded internally, in niches nobody else wants.

That’s the whole machine, and it has now run three times: paediatric endocrinology, metabolics, and paediatric dermatology in ninety days.

Obviously, this is no longer the setup it was in November.

Then, you were buying a cheap stock with binary catalysts attached and the market ignoring all of it.

Now you’re buying a business the market has noticed, where the return has to come from earnings growth rather than the multiple catching up.

What keeps me interested is that the forward numbers are still moving in the right direction faster than the price is. Q2 revenue annualises to $150 million against a 2027 exit target of $200 million that management now says they’re “well ahead” of. Margins are eight points ahead of the 2028 schedule. And the two biggest assets in the portfolio - ASN-001 and ET-700 - contribute nothing at all to current revenue.

The next two things I’m watching are the ET-700 pilot results, which are weeks away, and the Q3 HEMANGEOL number, which is the first clean read on the biggest revenue line in the business.

I’ll write both up when they land.

You can see every idea in the Model Portfolio, position by position, here:

The Model Portfolio

And the full archive of every thesis, update and screen I’ve published:

The Research Portal

Thanks for reading,

Nico

Disclaimer: This is not a recommendation to buy or sell any securities. The Content does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Nothing in this newsletter should be construed as a personal recommendation or advice to buy, sell, or hold any investment or security. All Content is provided for general informational purposes only and should not be relied upon for making investment decisions. You should not make any investment decision based solely on the Content without first consulting with qualified financial advisors, conducting your own research, and considering your individual financial circumstances, investment objectives, and risk tolerance. To read our full disclaimer, click here.